Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands.

Abstract

INTRODUCTION Respiratory syncytial virus (RSV) infection is one of the major causes of respiratory illness in infants, infecting virtually every child before the age of 2 years. Currently, several Phase 1 trials with RSV vaccines in infants are ongoing or have been completed. As yet, no efficacy estimates are available for these vaccine candidates… (More)
DOI: 10.1016/j.vaccine.2012.04.072

Topics

3 Figures and Tables

Slides referencing similar topics